近日，国家医保局针对部分企业药品垄断、虚增成本等问题，持续强化药品价格常态化监管。自2023年初以来，国家医保局综合运用监测预警、函询约谈、信用评价、信息披露等手段，有力有效处置一批通过虚抬原料药价格、倒逼制剂价格上涨的企业。据统计，2023年约谈药品平均降价幅度超过40%。
此次降价措施旨在维护患者合法权益，降低群众用药负担。国家医保局表示，将继续关注药品市场动态，严厉打击违法违规行为，保障药品价格合理稳定。
英文翻译：
News content:
Recently, the National Medical Security Bureau has strengthened the normalization of drug price supervision in response to issues such as monopoly and inflated costs in some enterprises. Since the beginning of 2023, the National Medical Security Bureau has effectively addressed a number of cases involving artificial price increases of raw materials and forced increases in the prices of formulations through the use of monitoring and early warning, consultation letters, credit evaluation, information disclosure, and other means. The average price reduction of the negotiated drugs exceeds 40%.
The purpose of this price reduction measure is to protect the legitimate rights and interests of patients and reduce the burden of medication for the public. The National Medical Security Bureau stated that it will continue to pay attention to the dynamics of the drug market, severely crack down on illegal and irregular behaviors, and ensure the rational and stable prices of drugs.
【来源】http://www.chinanews.com/gn/2024/01-05/10140901.shtml
Views: 1